



Corrigendum

Corrigendum to “Clinicopathological and prognostic significance of MUC13 and AGR2 expression in intraductal papillary neoplasms of pancreas” [Pancreatology 18 (2018) 407–412]



Kumiko Mito ^{a, b}, Michihiro Saito ^b, Kohei Morita ^a, Iruru Maetani ^b, Naohiro Sata ^c, Makiko Mieno ^d, Noriyoshi Fukushima ^{a, *}

^a Department of Pathology, Jichi Medical University, Japan

^b Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Japan

^c Department of Surgery, Jichi Medical University, Japan

^d Department of Medical Informatics, Center for Information Jichi Medical University, Japan

The authors regret four typos.

The authors show corrected text below.

p.408, right column.

“Immunohistochemistry” 2nd paragraph.

• The proportion of positive cancer cell staining was graded as follows: 0 (negative), <25% (1+), 25%–50% (2+), 50%–70%(3+), and >75% (4+).

→(correct description) 75%

p.409, right column.

“Results” 2nd paragraph.

• MUC13 was significantly expressed in the invasive carcinoma components ($p < 0.005$).

→(correct description) $p < 0.001$.

• MUC13 overexpression was not significantly associated with disease-free survival (DFS) ($p = 0.074$) (Fig. 3-A);

→(correct description) $p = 0.091$.

• however, it was significantly associated with overall survival (OS) ($p = 0.004$) (Fig. 3-B).

→(correct description) $p = 0.002$.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.pan.2018.04.003>.

* Corresponding author. Department of Pathology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan.

E-mail address: nfukushima@jichi.ac.jp (N. Fukushima).

<https://doi.org/10.1016/j.pan.2019.06.003>

1424-3903/© 2019 IAP and EPC. Published by Elsevier B.V. All rights reserved.